Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X:
Title: Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial
Authors: James M. Cleary, Christoph Springfeld, Dirk Arnold, Antoine Hollebecque, Olumide Gbolahan, Misako Nagasaka, Salvatore Siena, Frans Opdam, Yu Sunakawa, Philippe A. Cassier, Gaurav Trikha, Eelke H. Gort, Vaia Florou, Richard Greil, Paul F. La Porte, Pritesh J. Gandhi, Fiona Garner, Ernesto Wasserman, Shola Adeyemi, Alison M. Schram
Read the Full Article.
- ” ORR 36.8%,
- mDOR 7.4 months mPFS 9.2 mo
Rare GA in BTC, but effective treatment, broad NGS is key.”
Other articles featuring Arndt Vogel on OncoDaily.